Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $128.78 USD
Change Today +13.23 / 11.45%
Volume 6.4M
BMRN On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BMRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/27/15 - $133.54
52 Week Low
04/15/14 - $55.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

biomarin pharmaceutical inc (BMRN) Details

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.

1,681 Employees
Last Reported Date: 03/2/15
Founded in 1996

biomarin pharmaceutical inc (BMRN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $868.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $457.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $631.9K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Executive Vice President of Technical Operati...
Total Annual Compensation: $414.4K
Compensation as of Fiscal Year 2013.

biomarin pharmaceutical inc (BMRN) Key Developments

Shire Reportedly Looking To Buy BioMarin Pharma

There are market speculations that Shire plc (LSE:SHP) is considering acquiring BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) in a $65 billion deal. The shares of Shire rose today because of the merger speculations and UBS AG's confidence in Shire.

Myriad Genetics, Inc. Announces Expansion of Collaboration with BioMarin Pharmaceutical Inc

Myriad Genetics Inc. announced an expansion of the company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed. Talazoparib is an investigational poly-ADP ribose polymerase (PARP) inhibitor being developed by BioMarin. In the expanded relationship, the companies also will collaborate under FDA regulations and guidelines for the development and potential regulatory approval requirements for both talazoparib and myChoice HRD. The expansion adds to an ongoing collaboration that began in September 2013, when BioMarin began using Myriad's BRACAnalysis CDx companion diagnostic test in its pivotal Phase 3 EMBRACA and Phase 2 ABRAZO clinical studies of talazoparib for advanced or metastatic breast cancer patients carrying BRCA mutations.

AstraZeneca Reportedly Mulls Acquisition Of Biomarin Pharmaceuticals

AstraZeneca PLC (LSE:AZN) is reportedly seeking acquisition of BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN). “Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash,” British newspaper Daily Mail reported


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRN:US $128.78 USD +13.23

BMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $63.33 USD +0.39
Celgene Corp $118.68 USD +1.02
Jazz Pharmaceuticals PLC $175.42 USD +2.03
Regeneron Pharmaceuticals Inc $454.50 USD +6.13
Vertex Pharmaceuticals Inc $120.34 USD +2.74
View Industry Companies

Industry Analysis


Industry Average

Valuation BMRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.4x
Price/Book 12.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at